April 18th 2024
A novel scoring system including radiomics data may help clinicians identify the risk of central lymph node metastasis in patients with a subtype of thyroid cancer.
Community Practice Connections™: What’s Next for Patients with Breast Cancer, and How Can We Effectively Optimize PARP-, HER2/3-, and TROP2-Targeted Regimens in Treatment Plans?
View More
Patient, Provider and Caregiver Connection™: Addressing Patient Concerns During the Treatment and Management of HR+/HER2- Breast Cancer
View More
Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician
View More
Medical Crossfire®: Leveraging Multidisciplinary Teams in Early–Stage Breast Cancer When the Goal is Cure
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
23rd Annual International Congress on the Future of Breast Cancer® East
July 19-20, 2024
Register Now!
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Minimizing Dose Interruptions With Lenvatinib Improves PFS in Thyroid Cancer, Posthoc Analysis Shows
December 28th 2018Minimizing dose interruptions of lenvantinib improved progression-free survival in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC), according to an exploratory post-hoc analysis from a phase III randomized trial.
Read More
Novel Multikinase Inhibitor Demonstrates Efficacy in Unresectable MTC
December 28th 2018Promising efficacy was seen with anlotinib therapy in patients with unresectable locally advanced or metastatic medullary thyroid cancer in the form of durable antitumor responses, according to the results of a Chinese phase II study recently published in the journal <em>Thyroid</em>.
Read More
Larotrectinib Granted FDA Approval for NTRK+ Cancers
November 27th 2018The FDA has granted an accelerated approval to larotrectinib (Vitrakvi) for use in adult and pediatric patients with solid tumors that have an <em>NTRK</em> gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment.
Read More
Newer Targeted Therapies Making an Impact in Many Subtypes of Thyroid Cancer
November 27th 2018Targeted agents have produced new treatment options for patients with advanced thyroid cancers, with significant advances being seen this year in moving toward precision medicine for various thyroid cancer subtypes, according to Marcia S. Brose, MD, PhD.
Read More
Low-Dose Radiation As Effective as Standard Dose for Select Patients With Thyroid Cancer
November 27th 2018Patients with thyroid cancer classified as having low risk of disease recurrence can be treated safely with a lower dose of radiation following surgery, compared with the standard higher dose, according to long-term findings from the HiLo trial presented at the National Cancer Research Institute (NCRI) Cancer Conference.
Read More
Meta-Analysis Examines Risk for Subsequent Malignancy After Radioiodine Therapy for Thyroid Cancer
November 24th 2018More research is still needed to determine the risk of developing a subsequent malignant neoplasm following radioactive iodine treatment for thyroid cancer, according to findings that were presented during the Annual Meeting of the American Thyroid Association and published in <em>Thyroid</em>.
Read More
A Look Back at FDA News from October 2018
November 1st 2018A look back at all the FDA news that happened in the month of October 2018, including several new FDA approvals, priority reviews, a breakthrough therapy designation, and more, in a variety of cancer types.<br />
Read More
Despite Advances, Interpreting Data From Genomics and Precision Medicine Lags
October 25th 2018I think one of the most important advancements in biomedical technology that has improved our understanding of the complexities of cancer is the ability to sequence the cancer genome for any individual patient, in a rapid and cost-effective manner, to help us make treatment decisions in the clinic.
Read More
Financial Advocacy Grows Under the Value-Based System
October 24th 2018Groundbreaking developments in cancer therapies can change lives, extending survival and sending patients who previously thought their chances were slim into remission. But these therapies come at a cost, and many patients reel at the prospect of heavy financial burdens. To help patients and programs meet the challenges of affording cancer treatments, community cancer centers are expanding the role of financial advocates in their organizations.
Read More
ACCC President Reignites Resilience in Oncology Caregivers
October 23rd 2018Thomas A. Gallo, MS, MDA, president of the Association of Community Cancer Centers, discusses his mission as president to “reflect, renew, and reignite” in order to create a more resilient oncology team for the community.
Watch
Entrectinib Induces Responses Across Multiple Tumor Types
October 22nd 2018Among patients with advanced solid tumors associated with <em>NTRK</em> gene fusions, more than half had responses to the small-molecule inhibitor entrectinib, according to an integrated analysis of 3 clinical trials presented at the 2018 ESMO Annual Congress.
Read More
Larotrectinib Induces 80% ORR in Advanced NTRK+ Solid Tumors
October 22nd 2018Larotrectinib induced an objective response rate of 80% in patients with advanced solid tumors who harbored <em>NTRK </em>gene fusions, according to results pooled from 3 small trials of the TRK inhibitor. Results were presented during the 2018 ESMO Congress.
Read More
CMS Tackles Drug Prices, But What Does This Mean for Patient Care Access?
October 19th 2018Rising prescription drug prices continue to add to the burden of paying for quality healthcare. In an effort to confront such costs, the Centers for Medicare & Medicaid Services has rescinded a prohibition on step therapy for Medicare Advantage plans. But some contend such a policy will reduce patient access to optimal medication.
Read More
LOXO-292 Granted FDA's Breakthrough Designation for RET Fusion-Positive Thyroid Cancer
October 15th 2018LOXO-292 has been granted a breakthrough therapy designation by the FDA for treatment of patients with advanced RET fusion–positive thyroid cancer requiring systemic therapy, who have progressed on prior treatment and have no other acceptable alternative treatment options. Loxo Oncology, the developer of the selective RET inhibitor, released the news of the designation in a statement today.
Read More
IMRT With Chemotherapy Improves Survival, Locoregional Control in Thyroid Cancer
October 8th 2018Patients with nonanaplastic thyroid cancer who received concurrent chemotherapy with intensity-modulated radiation therapy had superior local progression-free survival and distant metastasis-free survival (DMFS) compared with those who received only IMRT, according to recently published results.
Read More
LOXO-292 Receives Breakthrough Designation From FDA for NSCLC, MTC
September 5th 2018LOXO-292 has been granted a breakthrough therapy designation by the FDA for the treatment of patients with <em>RET</em> fusion–positive non–small cell lung cancer or <em>RET</em>-mutant medullary thyroid cancer.
Read More